Paul Frohna

Dr. Paul Frohna is a physician-scientist with over 20 years of experience in the biotech industry with expertise in translational medicine, clinical trial design, and clinical and regulatory strategy. He has successfully designed and initiated translational and clinical programs for biologics, small molecules, and peptides, and has contributed to five approved medicines. 
He began his industry career at Genentech where he was clinical lead for the Rituxan Phase 2 program for relapsing and primary progressive MS. There he patented the use of B-cell depleting therapy for MS, which later led to the development of ocrelizumab.

He went on to be Vice President of Clinical Development at Fibrogen and later the Chief Medical Officer at Profibrix, before joining Receptos as Vice President of Clinical Development and Translational Medicine, where he oversaw clinical development of ozanimod (ZEPOSIA) for relapsing MS and other immunology programs. 
He subsequently held CMO roles at ImCheck Therapeutics and Endeavor Biosciences before becoming a consulting CMO for emerging biotech companies. 
Dr. Frohna received his pharmacy degree from the University of Texas at Austin College of Pharmacy, his PhD in Pharmacology from the University of Pennsylvania School of Medicine, and his MD from Georgetown University School of Medicine.